These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 23027660)

  • 21. Protein glycosylation and its impact on biotechnology.
    Berger M; Kaup M; Blanchard V
    Adv Biochem Eng Biotechnol; 2012; 127():165-85. PubMed ID: 21975953
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors influencing the immunogenicity of therapeutic proteins.
    Schellekens H
    Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi3-9. PubMed ID: 15958824
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Microtools for single-cell analysis in biopharmaceutical development and manufacturing.
    Love KR; Bagh S; Choi J; Love JC
    Trends Biotechnol; 2013 May; 31(5):280-6. PubMed ID: 23582471
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Global vision about the biological medicinal products: biosimilars (April, 2009).
    Zuñiga L; Calvo B
    Curr Pharm Biotechnol; 2009 Dec; 10(8):772-4. PubMed ID: 19939216
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FDA perspective on specifications for biotechnology products--from IND to PLA.
    Murano G
    Dev Biol Stand; 1997; 91():3-13. PubMed ID: 9413677
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recombinant protein production in bacterial hosts.
    Overton TW
    Drug Discov Today; 2014 May; 19(5):590-601. PubMed ID: 24246684
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Moss bioreactors producing improved biopharmaceuticals.
    Decker EL; Reski R
    Curr Opin Biotechnol; 2007 Oct; 18(5):393-8. PubMed ID: 17869503
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Application of quality by design principles to the development and technology transfer of a major process improvement for the manufacture of a recombinant protein.
    Looby M; Ibarra N; Pierce JJ; Buckley K; O'Donovan E; Heenan M; Moran E; Farid SS; Baganz F
    Biotechnol Prog; 2011; 27(6):1718-29. PubMed ID: 21948302
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bioreactor technology: a novel industrial tool for high-tech production of bioactive molecules and biopharmaceuticals from plant roots.
    Sivakumar G
    Biotechnol J; 2006 Dec; 1(12):1419-27. PubMed ID: 17136730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glycosylation profiles of therapeutic antibody pharmaceuticals.
    Wacker C; Berger CN; Girard P; Meier R
    Eur J Pharm Biopharm; 2011 Nov; 79(3):503-7. PubMed ID: 21745568
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity of therapeutic proteins. Part 1: impact of product handling.
    Sharma B
    Biotechnol Adv; 2007; 25(3):310-7. PubMed ID: 17336479
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Considerations in assessing the developmental and reproductive toxicity potential of biopharmaceuticals.
    Martin PL; Breslin W; Rocca M; Wright D; Cavagnaro J
    Birth Defects Res B Dev Reprod Toxicol; 2009 Jun; 86(3):176-203. PubMed ID: 19462404
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aqueous two-phase systems: A viable platform in the manufacturing of biopharmaceuticals.
    Rosa PA; Ferreira IF; Azevedo AM; Aires-Barros MR
    J Chromatogr A; 2010 Apr; 1217(16):2296-305. PubMed ID: 19962707
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rapid whole monoclonal antibody analysis by mass spectrometry: An ultra scale-down study of the effect of harvesting by centrifugation on the post-translational modification profile.
    Reid CQ; Tait A; Baldascini H; Mohindra A; Racher A; Bilsborough S; Smales CM; Hoare M
    Biotechnol Bioeng; 2010 Sep; 107(1):85-95. PubMed ID: 20506289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Post-translational modifications of protein biopharmaceuticals.
    Walsh G
    Drug Discov Today; 2010 Sep; 15(17-18):773-80. PubMed ID: 20599624
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biopharmaceuticals -- discovery, development and manufacturing.
    Jungbauer A; Graumann K
    Biotechnol J; 2012 Dec; 7(12):1422-3. PubMed ID: 23213011
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Practical approaches to dose selection for first-in-human clinical trials with novel biopharmaceuticals.
    Tibbitts J; Cavagnaro JA; Haller CA; Marafino B; Andrews PA; Sullivan JT
    Regul Toxicol Pharmacol; 2010 Nov; 58(2):243-51. PubMed ID: 20558225
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A role for protein misfolding in immunogenicity of biopharmaceuticals.
    Maas C; Hermeling S; Bouma B; Jiskoot W; Gebbink MF
    J Biol Chem; 2007 Jan; 282(4):2229-36. PubMed ID: 17135263
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biopharmaceutical discovery and production in yeast.
    Meehl MA; Stadheim TA
    Curr Opin Biotechnol; 2014 Dec; 30():120-7. PubMed ID: 25014890
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The state of biopharmaceutical manufacturing.
    Molowa DT; Mazanet R
    Biotechnol Annu Rev; 2003; 9():285-302. PubMed ID: 14650933
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.